藥師幫(9885.HK)獲納入恒生系列指數,有機會獲被動指數型基金買入
恒生指數有限公司於2月16日公佈了最新一期的恒生指數系列季度檢討結果。藥師幫(9885.HK)共獲納入10項指數,包括恒生綜合中型股指數、恒生綜合大中型股指數、恒生大中型股(可投資)指數、恒生港股通指數、恒生港股通中小型股指數、恒生港股通中國內地公司指數、恒生滬深港通大灣區綜合指數、恒生滬深港通大灣區廣佛肇指數、恒生滬深港通大灣區消費品指數,以及恒生滬深港通大灣區新經濟指數。相關變動將於 2024年3月4日起生效。恒生指數是香港主要的股票市場指數,涵蓋各個行業的代表性公司,是全球金融市場中備受關注的指數之一。該指數獲機構投資者廣泛認可,是眾多投資者尋求優質標的,優化投資組合的參考基準。據業內人士介紹,此次藥師幫被納入機構所跟蹤的相應指數,有機會獲得恒生中型股指數基金、廣發港股通恒生綜合中型股指數證券投資基金、方正富邦滬深港通大灣區綜合指數證券投資基金等被動指數型基金的資金配置,進一步增進公司個股流動性。據相關資料,藥師幫此前已獲得跟蹤中證港股通醫藥衞生綜合指數的港股醫藥ETF買入。此外,藥師幫更是獲得KWEB超1200萬股持倉(持倉數據更新至2024年2月15日)。KWEB全稱為KraneShares CSI China Internet ETF(KraneShares中國海外互聯網ETF),為一隻由美國基金公司發行,跟蹤中證海外中國互聯網指數32只成分股的基金。目前,KWEB的主要持倉包括騰訊控股、阿里巴巴、拼多多等多家知名互聯網公司。藥師幫此次被納入恒指10項指數,也意味着公司的經營表現及商業價值得到了資本市場的認可,將有利於進一步提升公司知名度、吸引更多投資者關注,股票流動性有望進一步提升。據瞭解,藥師幫是國內最大的院外醫藥產業數字化綜合服務平台,覆蓋國內37.9萬家下游藥店以及約21.1萬家基層診所。近年來,藥師幫在業績方面一直保持穩健增長。公司中期報吿顯示:截至2023年6月30日,藥師幫上半年GMV達到人民幣220.41億元,較2022年同期相比,增長34.4%。根據弗若斯特沙利文的資料,藥師幫2022年的市場份額為21.0%,行業排名第一。同時,藥師幫所處賽道仍處於上升期,成長空間巨大。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.